This is a single-institution, single-arm, open-label Phase 2 trial evaluating evofosfamide in subjects with M1 CRPC who fail first-line ARSIs. In those progressing after second-line Docetaxel or deemed ineligible to it, the use of alternate ARSI remains the most common line of therapy in our Province, in keeping with recent international recommendations. After baseline molecular imaging (PSMA and fluorodeoxyglucose (FDG) PET/CT), prior to evofosfamide initiation, subjects will be encouraged to undergo biopsy of a dominant lesion: FDG-, PSMA-uptake and/or conventional imaging determined (in order, and according to feasibility). Subjects will then receive the alternate ARSI (i.e., different from the one received in first line) as per current standard practice and Provincial drug plan coverage. Additionally, subjects will receive combinatorial evofosfamide at a dose of 480 mg/m2 intravenously (IV) over 60 minutes on Days 1, 8 and 15 of every 28-day cycle. Therapy will continue until disease progression, unacceptable toxicity as a result of evofosfamide, or subject withdrawal. Assessments during evofosfamide treatment will include history, physical exam, and blood tests at each monthly visit to monitor for toxicity. Response and progression will be evaluated by whole-body PSMA PET/CT scan every 8 weeks (± 3 days) and determined using (PE)RECIST v1.1 criteria. PSA, NE markers (e.g., Serum CHGA, NSE), organ function tests (e.g., liver, kidney) and investigational liquid biopsy samples will be followed every cycle (monthly). FDG PET/CT will be performed at baseline, at 6-10 weeks from the date of signing the informed consent form (ICF), and upon progression, irrespective of treatment discontinuation or initiation of another therapy. Subjects will be followed for survival endpoints following completion of this study treatment until death.

Start Date01 Apr 2025

Sponsor / Collaborator

University Health Network

[+1]

NCT06782555

/ RecruitingPhase 1/2

A Phase 1/2 Immunotherapy Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab in Patients with Advanced Solid Malignancies

The purpose of this Phase 1/2 study is to test the overall safety, tolerability, and effectiveness of the combination investigational drugs evofosfamide, zalifrelimab, and balstilimab in treating advanced or metastatic castration-resistant prostate cancer, pancreatic cancer, and human papilloma virus (HPV)-negative squamous cell carcinoma of the head and neck (SCCHN).

Start Date08 Jan 2025

Sponsor / Collaborator

Immunogenesis, Inc.

[+1]

NCT06014502

/ RecruitingPhase 1

A Phase 1a/1b, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of IMGS-001 in Patients With Relapsed or Refractory Advanced Solid Tumors

The purpose of this Phase 1a/1b clinical trial is to test the safety of an investigational drug called IMGS-001 and to determine how well it can work in treating patients with advanced solid tumors that have come back or are not improving after receiving other drugs that are commonly used for their cancer. Phase 1a (Part 1) will test the safety of five different doses of IMGS-001 to use in further studies. Patients with cancer that have advanced or spread to other parts of the body following treatment with other available therapies will be treated in Part 1. Phase 1b (Part 2) will test two doses of IMGS-001 identified in Part 1 to further determine the safety and potential effectiveness in select cancer types.

Start Date07 Sep 2023

Sponsor / Collaborator

Immunogenesis, Inc.

100 Clinical Results associated with Immunogenesis, Inc.

0 Patents (Medical) associated with Immunogenesis, Inc.

Literatures (Medical) associated with Immunogenesis, Inc.

21 Apr 2025·Cancer Research

Abstract 7304: Cytotoxic PD-L1/PD-L2 dual-specific antibodies couple tumor stroma remodeling with checkpoint blockade to drive rejection of “cold” cancers

Author: Boland, Nadthakarn ; Salameh, Ahmad ; Iezzi, Manuela ; Couillault, Coline ; Zha, Dongxing ; Liu, Qinying ; Curran, Michael A. ; Gagliardi, Christine ; Blezinger, Paul ; Cavallo, Federica ; Bolli, Elisabetta ; Pericle, Federica ; Srinivasamani, Anupallavi ; Prinz, Bianka ; Trusz, Guillaume

AbstractIntroduction:Antibody blockade of either the Programmed Death 1 (PD-1) immune checkpoint receptor on T cells or its cognate ligand PD-L1 on tumor cells and stroma has revolutionized oncology but fails to regress “cold” tumors lacking T cell infiltration. We leveraged the iterative selection capacity of yeast-displayed fully human antibody selection to identify dual PD-L1/PD-L2 specific antibodies (DIPDL) that block their engagement of both PD-1 and B7-1. Finally, we engineered these DIPDL to efficiently kill PD-L1 and PD-L2 expressing tumors and stroma.Materials and Methods:Antibody binding to PD-Ligands was measured by Octet. The Promega PD-1 assay system was used to measure EC50s for reversal of PD-1 driven T cell inhibition. Retrogenix microarray technology was used to determine specificity of target binding. Surrogate and direct assays were used to measure ADCC and ADCP efficiency. Murine syngeneic tumor models were tested for PD-1 blockade versus DiPDL antibodies to mediate tumor regression. Flow cytometry was used to characterize changes in the tumor immune microenvironment. Human tumor xenografts were implanted into immunodeficient mice to study the cytotoxic potential of these antibodies.Results:We leveraged multiple antibody engineering technologies to generate dual PD-L1/PD-L2 specific antibodies capable of blocking ligand interactions with PD-1 and B7-1, and also mediating efficient tumor and stromal depletion. These Fc engineered DIPDL kill human PD-L1+ and/or PD-L2+ cells in vitro using both NK and myeloid effectors. In vivo studies of murine syngeneic tumor models revealed that these DIPDL antibodies significantly outperform PD-1 blockade across both “hot” and “cold” cancers. Tumor microenvironment analysis showed that myeloid stromal depletion correlates with T cell and dendritic cell expansion and therapeutic response. Lastly, treatment of immunodeficient mice bearing human triple negative breast cancer with these cytotoxic DIPDL significantly inhibited tumor growth and reduced myeloid stromal density.Conclusions:These DIPDL represent a new generation of immunotherapeutic which couple superior PD-1 pathway blockade with direct depletion of both immunosuppressive and T-cell exclusionary stroma and tumors. Across murine models, these DIPDL deliver transformative efficacy overcoming limitations of simple PD-1 blockade and have moved to an ongoing Phase I clinical trial.Citation Format:Ahmad Salameh, Coline Couillault, Anupallavi Srinivasamani, Qinying Liu, Elisabetta Bolli, Christine Gagliardi, Guillaume Trusz, Nadthakarn Boland, Paul Blezinger, Dongxing Zha, Manuela Iezzi, Bianka Prinz, Federica Cavallo, Federica Pericle, Michael A. Curran. Cytotoxic PD-L1/PD-L2 dual-specific antibodies couple tumor stroma remodeling with checkpoint blockade to drive rejection of “cold” cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 7304.

21 Apr 2025·Cancer Research

Abstract 5846: A potent STING agonist induces endothelial PD-L1 and enhances antitumor efficacy of a novel PD-L1/PD-L2 antibody

Author: Ceci, Martina ; Conti, Laura ; Gagliardi, Christine ; Salameh, Ahmad ; Cossu, Chiara ; Cavallo, Federica ; Blezinger, Paul ; Curran, Michael A. ; Bolli, Elisabetta ; Lewis, Andrew ; Iezzi, Manuela ; Barlow, James ; Pericle, Federica

Background:The activation of stimulator of interferon genes (STING) has emerged as a promising strategy to reprogram the tumor microenvironment (TME) and enhance antitumor immunity. We previously demonstrated that combining a potent STING agonist (8803, IMGS-203) with a novel dual-specific anti-PD-L1/PD-L2 monoclonal antibody (27907) produced curative responses in checkpoint-refractory tumor models. In this study, we investigated the mechanisms underlying these effects by analyzing the TME of tumors treated locally with 8803 and systemically with 27907 using immunohistochemistry and flow cytometry.Objective:To evaluate the necrobiotic effects of the STING agonist 8803 combined with the cytotoxic anti-PD-L1/PD-L2 antibody 27907 across multiple tumor models by characterizing the TME and tumor vascularization.Methods:The efficacy of 8803 was assessed in vivo in combination with 27907 in murine melanoma (B16F10 expressing mouse PD-L2) and mammary adenocarcinoma (TS/A) models. Mice with established tumors received intratumor injections of 8803 (10 ug/dose, twice) and systemic administration of 27907 (10 mg/kg, twice weekly for three weeks). Tumors were harvested 32 days post-challenge and analyzed via H&E staining, IHC, and FACS to evaluate necrobiosis, immune cell infiltration, and vascularization.Results:The combination of 8803 with 27907 demonstrated robust antitumor activity in both melanoma and breast cancer models. IHC and FACS profiling revealed a significant increase in infiltrating myeloid cells alongside a notable reduction of the immunosuppressive M2 macrophage phenotype (CD206+). Intratumor 8803 markedly upregulated PD-L1 expression in endothelial cells, that were effectively disrupted by systemic 27907, as evidenced by increased caspace-3 and CD62p co-expression in endothelial cells within treated tumors. This endothelial disruption was absent in tumors treated with 8803 alone. Further, western blot and FACS analyses of human and murine endothelial cells co-cultured with 8803 confirmed upregulation of PD-L1 and PD-L2. Critically, PD-L1+/PD-L2+ endothelial cells were selectively eliminated by monocytic-enriched bone marrow-derived myeloid cells and PBMCs in the presence of 27907, suggesting a direct effect of the antibody on tumor vasculature.Conclusion:Tumors treated with the combination of 8803 and 27907 exhibited extensive necrobiosis and endothelial damage, uniquely observed in the combination treatment group and correlating with curative outcomes. This enhanced antitumor response was associated with increased myeloid infiltration, a shift away from M2 macrophage phenotype, and an elevated effector T-cell population. These findings underscore the potent therapeutic synergy of 8803 with 27907 and support their further development for clinical applications.Citation Format:Ahmad Salameh, Manuela iezzi, Andrew Lewis, Christine Gagliardi, Laura Conti, Elisabetta Bolli, Chiara Cossu, Martina CECI, Paul Blezinger, Michael A. Curran, Federica Cavallo, James Barlow, Federica Pericle. A potent STING agonist induces endothelial PD-L1 and enhances antitumor efficacy of a novel PD-L1/PD-L2 antibody [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 5846.

News (Medical) associated with Immunogenesis, Inc.

06 Mar 2025

·www.prnewswire.com

ImmunoGenesis Doses First Patient in Phase 1/2 Clinical Trial of IMGS-101 in Combination With Balstilimab (anti-PD-1) and Zalifrelimab (anti-CTLA-4) in Relapsed or Refractory Advanced Prostate, Pancreatic, and HPV(-) Head & Neck Tumors

IMGS-101 is the only known reducer of solid tumor hypoxia, offering the potential to enhance the efficacy of immunotherapy HOUSTON, March 6, 2025 /PRNewswire/ -- ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, today announced the first patient has been dosed in the company's Phase 1/2 clinical trial of its hypoxia reversal agent IMGS-101 (evofosfamide) in combination with Balstilimab (anti-PD-1) and Zalifrelimab (anti-CTLA-4) at The University of Texas MD Anderson Cancer Center in Houston, Texas. Tumor hypoxia (low oxygen levels) is an immunosuppressive factor in solid tumors. By reversing hypoxia, IMGS-101 may improve the efficacy of immunotherapies in cancer types that are otherwise resistant to immune-based treatments. Continue Reading ImmunoGenesis The Phase 1/2, open-label, multicenter study (NCT06782555) consists of a dose escalation and expansion portion to evaluate the safety, pharmacokinetics, and anti-tumor activity of IMGS-101 in combination with Balstilimab and Zalifrelimab in adult patients with locally advanced or metastatic castration-resistant prostate cancer (CRPC), pancreatic cancer, and human papillomavirus-(HPV) negative squamous cell carcinoma of the head and neck (SCCHN). The study is being conducted in collaboration with Agenus, a clinical-stage immuno-oncology company developing the checkpoint inhibitors Balstilimab and Zalifrelimab. "Launching this trial represents a significant milestone in our mission to target key mechanisms of immune resistance," said ImmunoGenesis President and CEO James Barlow. "By targeting and reversing hypoxia, we aim to unlock the immune system's full potential and redefine the therapeutic landscape for these cancers with high unmet medical needs." "This trial marks an exciting step forward in addressing one of the key challenges in cancer immunotherapy," said Dr. Charles Schweizer, Senior Vice President of Clinical Development at ImmunoGenesis. "Hypoxia limits T-cell infiltration and suppresses immune responses, especially in prostate, pancreatic, and head and neck cancers. By reversing hypoxia, IMGS-101 may restore T-cell access to tumors, enhancing the effectiveness of checkpoint inhibitors and potentially transforming outcomes in these hard-to-treat cancers." About ImmunoGenesis ImmunoGenesis is a clinical-stage biotech company dedicated to transforming immuno-oncology by targeting key mechanisms of immune resistance. The company's lead product, IMGS-001, is a cytotoxic, dual-specific PD-L1/PD-L2 antibody currently in a phase 1a/b clinical trial for the treatment of immune-excluded ("cold") tumors, which account for more than half of all cancers. In addition to its lead program, the company is developing a number of novel approaches to overcome immune resistance in cold tumors. ImmunoGenesis designs therapies to address the pathology of these tumors, overcoming immune exclusion to elicit a robust immune response. For more information, visit . About IMGS-101 IMGS-101, also known as Evofosfamide, is a 2-nitroimidazole prodrug of the cytotoxin bromo-isophosphoramide mustard (Br-IPM) originally developed as a hypoxia-activated prodrug. ImmunoGenesis' Founder, Dr. Michael A. Curran from MD Anderson, demonstrated in his lab that IMGS-101 has the unique ability to address one of the most significant immunosuppressive barriers by reversing hypoxia. In pre-clinical models and a Phase 1 clinical study, IMGS-101 restored T-cell function and showed early signs of synergizing with checkpoint inhibitors. ImmunoGenesis is developing IMGS-101 as a hypoxia-reversal agent that can condition tumors to respond to checkpoint inhibition. About Balstilimab Balstilimab is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting with its ligands PD-L1 and PD-L2. It has been evaluated in >900 patients to date and has demonstrated clinical activity and a favorable tolerability profile in several tumor types. Balstilimab is being developed by Agenus, Inc. About Zalifrelimab Zalifrelimab is a novel, fully human monoclonal immunoglobulin G1 (IgG1) designed to block CTLA-4 (cytotoxic T-lymphocyte associated antigen 4) from interacting with its ligands CD80 and CD86. CTLA-4 is a negative regulator of immune activation that is considered a foundational target within the immuno-oncology market. Zalifrelimab is being developed by Agenus, Inc. Disclosure Dr. Curran's financial relationship with ImmunoGenesis is managed and monitored by the MD Anderson Conflict of Interest Committee. Contact ImmunoGenesis Investors: James Barlow President and CEO [email protected] SOURCE Immunogenesis Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

ImmunotherapyPhase 1Clinical Result

11 Dec 2024

·www.globenewswire.com

PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy

PETACH TIKVA, Israel, Dec. 11, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced a new research and development collaboration with ImmunoGenesis, Inc. (“ImmunoGenesis”), a Houston-based clinical-stage biotechnology company developing science-driven immunotherapies. The collaboration focuses on the development of novel formulations utilizing PolyPid’s experience with its proprietary PLEX Technology and ImmunoGenesis’ potent STimulator of INterferon Genes (STING) agonist drug candidate to potentially enhance treatment for solid tumors. “We are very pleased to announce this collaboration with ImmunoGenesis and leverage PolyPid’s experience with PLEX technology which enables controlled and prolonged intratumoral drug delivery, with ImmunoGenesis’ potent anti-tumor STING agonist, potentially creating a cutting-edge approach in immuno-oncology,” said Dikla Czaczkes Akselbrad, PolyPid’s Chief Executive Officer. “The PLEX technology platform offers potential options for drug candidates with delivery challenges, and we will continue to explore additional opportunities to bring value through innovative collaborations.” The collaboration aims to address challenges of potent STING agonists which are susceptible to rapid clearance when administered intratumorally, limiting the exposure time within the tumor microenvironment for effective anti-tumor activity. About PolyPidPolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma.For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn. Forward-looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, PolyPid is using forward-looking statements when it discusses the potential of the collaboration to improve patient outcomes and to represent a cutting-edge approach in immuno-oncology, the potential of immunotherapy to address a broader group of patients, future collaboration between ImmunoGenesis and PolyPid, and that PolyPid will continue to explore additional opportunities to bring value through innovative collaborations. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting PolyPid, reference is made to PolyPid’s reports filed from time to time with the Securities and Exchange Commission, including, but not limited to, the risks detailed in PolyPid’s Annual Report on Form 20-F filed on March 6, 2024. Forward-looking statements speak only as of the date the statements are made. PolyPid assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If PolyPid does update one or more forward-looking statements, no inference should be drawn that it will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites. Contacts: PolyPid Ltd. Ori WarshavskyCOO – US908-858-5995IR@Polypid.com Investors:Brian RitchieLifeSci Advisors212-915-2578BRitchie@lifesciadvisors.com

ImmunotherapyPhase 3

28 Sep 2023

·www.biospace.com

ImmunoGenesis Doses First Patient in Phase 1a/1b Clinical Trial of IMGS-001 in Relapsed or Refractory Advanced Solid Tumors

[28-September-2023] IMGS-001 is the first dual-specific PD-L1/PD-L2 antibody with cytotoxic function designed to treat immune-excluded cancers that are resistant to existing immunotherapies HOUSTON, Sept. 28, 2023 /PRNewswire/ -- ImmunoGenesis, a clinical-stage biotechnology company developing science-driven immunotherapies, today announced the first patient has been dosed in the company's Phase 1a/1b clinical trial of its lead candidate, IMGS-001, at The University of Texas MD Anderson Cancer Center in Houston, Texas. IMGS-001 is a dual-specific programmed cell death 1 ligand 1 (PD-L1)/programmed cell death 1 ligand 2 (PD-L2) antibody engineered with cytotoxic function designed to treat cold, immune-excluded tumors, which are resistant to existing immunotherapy. The Phase 1a/1b first-in-human, open-label, multicenter study (NCT06014502) consists of a dose escalation and expansion portion to evaluate the safety, pharmacokinetics and preliminary anti-tumor activity of IMGS-001 in adult patients with locally advanced or metastatic solid tumors refractory to standard-of-care treatment. Anticipated tumor types in the dose escalation portion of the study include ovarian, colorectal and triple-negative breast cancer. "Many tumors are not responsive to the current immunotherapies, representing a significant unmet need," said ImmunoGenesis President and CEO James Barlow. "Our vision is to unlock the potential of immunotherapy for a broader group of patients by targeting key mechanisms of immune resistance. We believe that this study will deliver initial proof of concept for our groundbreaking multitasking approach of using a single molecule to address immunosuppression and PD-1 pathway blockade." "PD-L1 and PD-L2 are widely expressed not only on various tumors but also on immunosuppressive cells in the tumor microenvironment," said ImmunoGenesis Acting Chief Medical Officer Dr. Jeremy Barton. "IMGS-001 is designed to remove these immunosuppressive cells and potentially improve PD-1 pathway blockade. This Phase 1a/1b clinical trial is an important first step towards validating this approach as potentially effective in treating cold, immune-excluded cancers." About IMGS-001, a PD-L1/PD-L2 Dual-Specific Inhibitor IMGS-001, the lead program at ImmunoGenesis, is a PD-L1/PD-L2 dual-specific monoclonal antibody with engineered cytotoxic effector function. IMGS-001 is the first molecule in clinical testing to target PD-L2 in addition to PD-L1, potentially improving blockade of the PD-1 pathway. The engineered effector function may enable IMGS-001 to eliminate immunosuppressive PD-L1- and/or PD-L2-expressing cells present in the tumor microenvironment, providing the potential to overcome immune resistance in immune-excluded tumors. Preclinical data showed that IMGS-001 drove higher response rates in head-to-head studies compared to currently available immunotherapies. IMGS-001 may provide a new foundational therapy with its innovative multitasking mechanism of superior blockade and cytotoxic effector function. This work was conducted with support from the Cancer Prevention and Research Institute of Texas (CPRIT) DP200094 as well as an investment from the Cancer Focus Fund, LP. About ImmunoGenesis ImmunoGenesis is a clinical-stage immuno-oncology biopharmaceutical company re-envisioning the treatment of cold tumors, particularly of immune-excluded tumors. Immune-excluded tumors, which account for more than half of all cancers, are characterized by having mechanisms of resistance that suppress the immune response. ImmunoGenesis is creating therapies based on the pathology of these tumors that are rationally designed to overcome immune exclusion and thereby drive an effective immune response. For more information, visit Contacts ImmunoGenesis Investors: James Barlow President and CEO James.barlow@immunogenesis.com Media: Jennifer Guinan Sage Strategic Marketing jennifer@sagestrat.com

ImmunotherapyClinical Study

100 Deals associated with Immunogenesis, Inc.

100 Translational Medicine associated with Immunogenesis, Inc.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 14 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

Preclinical

Phase 1 Clinical

Phase 2 Clinical

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Evofosfamide ( DNA )	Pancreatic Cancer More	Phase 2
IMGS-001 ( PDL1 x PDL2 )	Colorectal Cancer More	Phase 1
27907(Immunogenic) ( PDL1 x PDL2 )	Neoplasms More	Preclinical
IMGS-203 ( STING )	Solid tumor More	Preclinical
IMGS-501 ( PDL1 x PDL2 )	Solid tumor More	Preclinical

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis